How Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
